Conclusively, inhibiting pro-angiogenic molecules including vascular endothelial growth factors (VEGFs) or their cognate receptors (VEGFRs), served as anti-angiogenic therapy approaches in advanced stage NSCLC patients, as well as other cancer entities, at the beginning of this century (Sandler et al., 2006) and reviewed in Jayson et al. (2016). This evidence concerns the gene VEGFA and cancer.